# MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

> **NCT00722371** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1615 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin phosphate
- **DRUG:** Pioglitazone hydrochloride
- **DRUG:** Matching placebo to sitagliptin
- **DRUG:** Matching placebo to pioglitazone
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00722371
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-05
- **Primary completion:** 2010-10-26
- **Final completion:** 2011-03-25
- **Target enrollment:** 1615 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00722371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00722371, "MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00722371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*